|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Prevention |
| Condition: |
Postoperative Nausea and Vomiting |
| Interventions: |
Drug: Aprepitant + Dexamethasone Drug: Ondansetron + Dexamethasone |
Participant Flow
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| The study took place at Duke University Medical Center from September 2007 to June 2009 |
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
| Description | |
|---|---|
| Aprepitant | Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia |
| Ondansetron | Ondansetron 4 mg within 30 minutes of the end of surgery + Dexamethasone 10 mg after induction of anesthesia |
| Aprepitant | Ondansetron | |
|---|---|---|
| STARTED | 52 | 55 |
| COMPLETED | 51 | 53 |
| NOT COMPLETED | 1 | 2 |
| prolonged postoperative ventilation | 1 | 2 |
Baseline Characteristics
| Description | |
|---|---|
| Aprepitant | Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia |
| Ondansetron | Ondansetron 4 mg within 30 minutes of the end of surgery + Dexamethasone 10 mg after induction of anesthesia |
| Aprepitant | Ondansetron | Total | |
|---|---|---|---|
|
Number of Participants
[units: participants] |
52 | 55 | 107 |
|
Age
[units: participants] |
|||
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 52 | 55 | 107 |
| >=65 years | 0 | 0 | 0 |
|
Age
[units: years] Mean ± Standard Deviation |
51 ± 13 | 48 ± 13 | 50 ± 13 |
|
Gender
[units: participants] |
|||
| Female | 30 | 28 | 58 |
| Male | 22 | 27 | 49 |
|
Region of Enrollment
[units: participants] |
|||
| United States | 52 | 55 | 107 |
Outcome Measures
| 1. Primary: | Cumulative Incidence of Emesis [ Time Frame: 48 h ] |
| 2. Secondary: | Incidence of Nausea [ Time Frame: PACU ] |
| 3. Secondary: | Incidence of Nausea [ Time Frame: 24 h ] |
| 4. Secondary: | Incidence if Nausea [ Time Frame: 48 h ] |
| 5. Secondary: | Incidence of Vomiting [ Time Frame: PACU ] |
| 6. Secondary: | Incidence of Vomiting [ Time Frame: 24 h ] |
| 7. Secondary: | Use of Rescue Antiemetics [ Time Frame: PACU ] |
| 8. Secondary: | Use of Rescue Antiemetics [ Time Frame: 24 h ] |
| 9. Secondary: | Use of Rescue Antiemetics [ Time Frame: 48 h ] |
| 10. Secondary: | Complete Response Rate [ Time Frame: PACU, 24 h, 48 h ] |
| 11. Secondary: | Nausea Scores [ Time Frame: PACU, 24 h, 48 h ] |
| 12. Secondary: | Number of Vomiting Episodes [ Time Frame: 48 h ] |
| 13. Secondary: | Time to First Vomiting [ Time Frame: 48 h ] |
| 14. Secondary: | Patient Satisfaction [ Time Frame: 48 h ] |
More Information
| Principal Investigators are NOT employed by the organization sponsoring the study. |
| There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
| Responsible Party: | Ashraf Habib, Duke University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00734929 History of Changes |
| Other Study ID Numbers: | 1404 |
| Study First Received: | August 13, 2008 |
| Results First Received: | April 7, 2011 |
| Last Updated: | May 5, 2011 |
| Health Authority: | United States: Institutional Review Board |